STRATEC SE

Earnings Release • Apr 25, 2006

News Details

Ad-hoc | 25 April 2006 14:32

STRATEC doubles earnings in the first quarter of 2006

Ad hoc announcement transmitted by DGAP – a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. —————————————————————————— STRATEC doubles earnings in the first quarter of 2006 Birkenfeld, April 25, 2006 The Board of Management of STRATEC Biomedical Systems AG, which is listed in the Prime Standard and Gate-M segments, hereby announces the preliminary unaudited consolidated figures for the STRATEC Group for the first quarter of the 2006 financial year as of March 31, 2006 in accordance with IFRS (International Financial Reporting Standards) pursuant to Section 15 of the German Securities Trading Act (WpHG). Key Figures (EUR 000s) 01.01.- 01.01.- Change 03.31.2006 03.31.2005 Sales 15,359 10,097 + 52.1% Gross performance 15,258 10,651 + 43.3% EBITDA 2,422 1,408 + 72.0% EBIT 2,152 1,188 + 81.1% EBT 2,156 1,140 + 89.1% Consolidated net income 1,583 719 + 120.2% Earnings per share (EUR) 0.43 0.22 + 95.5% The STRATEC Group, including Sanguin, had a total of 206 employees as of March 31, 2006 (previous year: 179). In line with IFRS 3 (Business Combinations), the income statement of Sanguin has not been consolidated in the consolidated income statement of the STRATEC Group for the first quarter of 2006. In contrast to the balance sheet consolidation, which was already undertaken in the first quarter of 2006, the consolidation of the income statement of the profitable company Sanguin for the second quarter of 2006 will be undertaken pursuant to the aforementioned standard in the interim report for the first half of 2006. ————————————————————————— Informationen und Erläuterungen des Emittenten zu dieser Ad-Hoc-Mitteilung: As a result of the time-consuming new consolidation of the balance sheet mainly due to the acquisition of the Anglo-American software company Sanguin in March 2006, the publication of the extensive interim report for the first quarter of 2006 will be postponed by one week. The interim report will therefore be available for downloading from our internet site from around 3 p.m. on May 17, 2006. Annual Results Telephone Conference – this year’s annual results telephone conference will be held at 10.00 a.m. on Thursday, April 27, 2006 on the occasion of the publication of our 2005 Annual Report (conference language: German). Following a brief résumé, Marcus Wolfinger, CFO of STRATEC Biomedical Systems AG, will be available to answer questions from the participating press representatives, investors and analysts. The dial-in number for the teleconference is: +49 (0)69 589 990 690. Upon request, we would be pleased to speak with English-speaking investors following the telephone conference. The 2005 Annual Report and the presentation for the annual results telephone conference will be available for downloading from our internet site from 8.00 a.m. on Thursday, April 27, 2006. About STRATEC STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de) designs and manufactures fully automated systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, to laboratories and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (SIN: 728900 / ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange, in the Gate-M trading segment of the Stuttgart Stock Exchange and on other exchanges. The STRATEC Group comprises the listed holding company ‘STRATEC Biomedical Systems AG’, as well as the subsidiaries ‘STRATEC NewGen’, ‘Robion’ and ‘Sanguin’. Further information can be obtained from: STRATEC Biomedical Systems AG André Loy, Investor Relations Gewerbestrasse 37, 75217 Birkenfeld Germany Tel: +49 7082 7916-190 Fax: +49 7082 7916-999 E-Mail: ir@stratec-biomedical.de (c)DGAP 25.04.2006 ————————————————————————— language: English emitter: STRATEC Biomedical Systems AG Gewerbestraße 37 75217 Birkenfeld Deutschland phone: +49 (0)7082 7916 0 fax: +49 (0)7082 7916 999 email: info@stratec-biomedical.de WWW: www.stratec-biomedical.de ISIN: DE0007289001 WKN: 728900 indexes: stockmarkets: Geregelter Markt in Frankfurt (Prime Standard), Stuttgart; Freiverkehr in Berlin-Bremen, München, Hamburg, Düsseldorf End of News DGAP News-Service —————————————————————————